Oruka says ORKA-001 hits 71.4% PASI 100 at Week 28 in EVERLAST-A psoriasis trial
O
ORKA• Week 52 data for all patients are expected in December 2026; initial EVERLAST-B Phase 2b data are due in 4Q 2026.
Week 28 results from EVERLAST-A
Oruka Therapeutics reported positive Week 28 results from its ongoing EVERLAST-A Phase 2a trial of ORKA-001 in plaque psoriasis.
- Responses continued to deepen months after the last induction dose, supporting a potential infrequent-dosing profile.
- Patients switching from placebo later in the study showed similar clearance patterns to those treated initially.
- Safety remained favorable through Week 28, with no new tolerability issues flagged.
